Piovesana L G, Torres F R, Azevedo P C, Amaral T P, Lopes-Cendes I, D'Abreu A
Department of Neurology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Department of Medical Genetics, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Acta Neurol Scand. 2017 Feb;135(2):183-188. doi: 10.1111/ane.12579. Epub 2016 Mar 4.
The prevalence of DYT1 (mutation in TOR1A) and DYT6 (mutation in THAP1) may vary in different populations, which can have important implications in clinical investigation. Our goal was to characterize patients with inherited and isolated dystonia and determine the frequency of mutations responsible for DYT1 and DYT6 in Brazilian patients.
Two movement disorder specialists examined 78 patients with idiopathic isolated dystonia using a standardized questionnaire, before sequencing TOR1A and THAP1 genes.
Clinically, our cohort was similar to those described in the international literature. Molecular studies of 68 subjects revealed only one potentially deleterious variant in THAP1 (1/68 patients, 1.47%). This was a novel 10-bp deletion at the end of exon 1, g.5308_5317del (ng_011837.1), which is predicted to create an alternative splicing and the insertion of a premature stop codon. Although we did not observe any potentially deleterious mutations in TOR1A, we found the missense variant rs1801968 (TOR1A p.D216H), previously reported as either a modifier of dystonia phenotype or a predisposing factor for dystonia. However, we did not identify any phenotypic impact related to the missense variant rs1801968 (P = 0.3387).
Although clinically similar to most cohorts with dystonia worldwide, the classical mutation (c.907_909delGAG) in TOR1A (causing DYT1) is absent in our patients. However, we found a potentially deleterious THAP1 mutation not previously reported. In addition, we found no association of rs1801968 with dystonia.
DYT1(TOR1A 突变)和 DYT6(THAP1 突变)的患病率在不同人群中可能有所不同,这对临床研究可能具有重要意义。我们的目标是对遗传性孤立性肌张力障碍患者进行特征描述,并确定巴西患者中导致 DYT1 和 DYT6 的突变频率。
两名运动障碍专家在对 TOR1A 和 THAP1 基因进行测序之前,使用标准化问卷对 78 例特发性孤立性肌张力障碍患者进行了检查。
在临床上,我们的队列与国际文献中描述的队列相似。对 68 名受试者的分子研究仅在 THAP1 中发现了一个潜在有害变体(68 例患者中的 1 例,1.47%)。这是外显子 1 末端的一个新的 10 碱基缺失,g.5308_5317del(ng_011837.1),预计会导致选择性剪接并插入一个提前终止密码子。虽然我们在 TOR1A 中未观察到任何潜在有害突变,但我们发现了错义变体 rs1801968(TOR1A p.D216H),此前该变体被报道为肌张力障碍表型的修饰因子或肌张力障碍的易感因素。然而,我们未发现与错义变体 rs1801968 相关的任何表型影响(P = 0.3387)。
尽管在临床上与全球大多数肌张力障碍队列相似,但我们的患者中不存在 TOR1A 中的经典突变(c.907_909delGAG,导致 DYT1)。然而,我们发现了一个此前未报道的潜在有害 THAP1 突变。此外,我们未发现 rs1801968 与肌张力障碍之间存在关联。